
Chimerix (CMRX) Stock Forecast & Price Target
Chimerix (CMRX) Analyst Ratings
Bulls say
Chimerix Inc. recently received FDA acceptance for its New Drug Application (NDA) seeking accelerated approval for dordaviprone, a treatment for recurrent H3 K27M-mutant diffuse glioma, highlighting the company’s potential for near-term commercialization opportunities. Additionally, Chimerix has announced a definitive agreement with Jazz Pharmaceuticals for acquisition at $8.55 per share, amounting to a total value of approximately $935 million, which signifies a substantial premium and reflects market confidence in Chimerix's strategic direction. Furthermore, the amended loan agreement for up to $30 million positions the company to enhance its financial stability as it advances its product pipeline.
Bears say
Chimerix Inc. has been downgraded due to the recently announced acquisition, prompting a revision in its rating and a price target adjustment to $8.55, reflecting the acquisition price. This downgrade may indicate concerns over the company's stability and growth potential following the acquisition, suggesting potential challenges in its financial outlook. Furthermore, the reliance on revenue from non-refundable upfront fees, royalties, and milestone payments may leave the company vulnerable to fluctuations in cash flow and profitability.
This aggregate rating is based on analysts' research of Chimerix and is not a guaranteed prediction by Public.com or investment advice.
Chimerix (CMRX) Analyst Forecast & Price Prediction
Start investing in Chimerix (CMRX)
Order type
Buy in
Order amount
Est. shares
0 shares